Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 113

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 113
---
 $1 million, subject to shareholder approval. The initial closing of the offering closed in the amount of $500,000, with the approval of certain items in NLS’s extraordinary general meeting on January 7, 2025, resulting in an issuance of 161,290 Common Shares to the Selling Shareholder.

Pursuant to the terms of the December SPA, the Company also agreed that on or before January 9, 2025, the Company would authorize and reserve sufficient Common Shares to satisfy the anti-dilution and ratchet rights of the Selling Shareholder under the October Debt SPA entered into on October 9, 2024, after giving effect to the conversion price reduction of the preferred shares as a result of the Dilutive Issuances (as defined in the October SPA) caused by the Company entering into the December SPA. On or before January 7, 2024, we authorized and reserved sufficient Common Shares to satisfy the anti-dilution and ratchet rights of the Selling Shareholder under the October Debt SPA. We further issued to the Selling Shareholder in accordance therewith the entire amount of ratchet securities, with the approval of certain items in NLS’s extraordinary general meeting on January 7, 2025, as follows: 408,871 PPCs convertible into Common Shares, and (ii) 75,000 Common Shares.

In connection with and pursuant to the registration rights provision of the December SPA, the Company agreed to register the Common Shares subject to the terms of the previously executed registration rights agreement dated October 9, 2024, or the Registration Rights Agreement.

Within the past three years, the Selling Shareholder has not held a position as an officer or a director of ours, nor has the Selling Shareholder had any material relationship of any kind with us or any of our affiliates. All information with respect to share ownership has been furnished by the Selling Shareholder, unless otherwise noted. The Common Shares being offered are being registered to permit public secondary trading of such Common Shares and the Selling Shareholder may offer all or part of the Common Shares it owns for resale from time to time pursuant to this prospectus. The Selling Shareholder does not have any family relationships with our officers, directors or controlling shareholders.

The term “Selling Shareholder(s)” also includes any transferees, pledgees, donees, or other successors in interest to the Selling Shareholder named in the table below. Unless otherwise indicated, to our knowledge, the person named in the table below has sole